{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:23:36Z","timestamp":1787261016157,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctro.2026.101246","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:21:45Z","timestamp":1785424905000},"page":"101246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Stereotactic body radiotherapy for bone-only oligometastatic bladder Cancer: a multi-institutional experience"],"prefix":"10.1016","volume":"60","author":[{"given":"Burak","family":"Tilki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan Cem","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birhan","family":"Demirhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pervin","family":"Hurmuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fenur","family":"Elmal\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolunay","family":"Kumru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokhan","family":"Ozyigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Onal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101246_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctro.2026.101246_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16183201","article-title":"Oligometastatic urothelial Cancer and stereotactic body radiotherapy: a systematic review and an updated insight of current evidence and future directions","volume":"16","author":"Angrisani","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctro.2026.101246_bb0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clon.2020.07.008","article-title":"Stereotactic body radiation therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and other urothelial malignancies","volume":"33","author":"Franzese","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ctro.2026.101246_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102373","article-title":"Metastasis-directed radiation therapy with consolidative intent for oligometastatic urothelial carcinoma: a systematic review and meta-analysis","volume":"14","author":"Longo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctro.2026.101246_bb0025","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2026.101246_bb0030","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101246_bb0035","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.euros.2023.08.003","article-title":"Defining Oligometastatic bladder Cancer: a systematic review","volume":"55","author":"Bamias","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.ctro.2026.101246_bb0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101246_bb0045","article-title":"Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: a retrospective experience","volume":"19","author":"Francolini","year":"2019","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ctro.2026.101246_bb0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13014-024-02465-y","article-title":"Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience","volume":"19","author":"Svedman","year":"2024","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2026.101246_bb0055","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.7150\/jca.28706","article-title":"Bone metastases pattern in newly diagnosed metastatic bladder Cancer: a population-based study","volume":"9","author":"Zhang","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.ctro.2026.101246_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13010054","article-title":"Bone metastasis in bladder cancer","volume":"13","author":"Yi","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.ctro.2026.101246_bb0065","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM task group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.ctro.2026.101246_bb0070","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.juro.2013.11.004","article-title":"Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan","volume":"191","author":"Abe","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.ctro.2026.101246_bb0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s10147-011-0350-z","article-title":"Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?","volume":"18","author":"Bekku","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101246_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.09.009","article-title":"Metastasectomy in older adults with urothelial carcinoma: population-based analysis of use and outcomes","volume":"36","author":"Faltas","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctro.2026.101246_bb0085","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/iju.13773","article-title":"Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: a retrospective case series","volume":"25","author":"Leonetti","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.ctro.2026.101246_bb0090","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4149\/neo_2018_180522N333","article-title":"Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy?","volume":"66","author":"Augugliaro","year":"2019","journal-title":"Neoplasma"},{"key":"10.1016\/j.ctro.2026.101246_bb0095","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.urolonc.2021.05.005","article-title":"Metastasis-directed radiation therapy after radical cystectomy for bladder cancer","volume":"39","author":"Miranda","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctro.2026.101246_bb0100","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaoncol.2023.2132","article-title":"Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors: the CHEERS phase 2 randomized clinical trial","volume":"9","author":"Spaas","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctro.2026.101246_bb0105","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2026.101246_bb0110","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder Cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2026.101246_bb0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab Vedotin plus Pembrolizumab in previously untreated advanced urothelial Cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101246_bb0120","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:25:16Z","timestamp":1787257516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"alternative-id":["S2405630826001412"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101246","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiotherapy for bone-only oligometastatic bladder Cancer: a multi-institutional experience","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101246"}}